Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine plus CAOLD in Relapsed/Refractory Peripheral T-Cell Lymphomas
NCT06176027Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in angioimmunoblastic T-cell lymphoma (AITL). Started Oct 2024; status: recruiting.
02
Drugs
azacitidine
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT06176027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176027.